and alprazolam clearance: differential kinetic and dynamic consequences. Clin
Pharmacol Ther 1998;64:237–247.
Guengerich FP. Safety assessment of stable drug metabolites. Chem Res Toxicol
2006;19:1559–1560.
Hastings KL, El-Hage J, Jacobs A, Leighton J, Morse D, Osterberg RE. Drug
metabolites in safety testing. Toxicol Appl Pharmacol 2003;190:93–94.
Hillebrand-Haverkort ME, Prummel MF, TenVeen JH. Ritonavir-induced Cushing’s
syndrome in a patient treated with nasal fluticasone. AIDS 1999;13:1803.
Humphreys WG, Unger SE. Safety assessment of drug metabolites: characterization of
chemically stable metabolites. Chem Res Toxicol 2006;19:1564–1569.
ICH. S3A––Toxicokinetics: the assessment of systemic exposure in toxicity studies;
1995a.
ICH. S1C––Dose selection for carcinogenicity studies of pharmaceuticals;1995b.
ICH. E6––Good clinical practice: consolidated guideline;1997.
ICH. Q2B––Validation of analytical procedures: methodology;1997.
ICH. M4: The CTD––Safety;2001.
ICH. Validation of analytical procedures: text and methodology;2005.
ICH. Q3B(R) impurities in new drug products (Revision 2);2006.
Iyer L, King CD, Whitington PF, Green MD, Roy SK, Tephly TR, Coffman BL,
Ratain MJ. Genetic predisposition to the metabolism of irinotecan (CPT-11): role of
uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of
its active metabolite (SN-38) in human liver microsomes. J Clin Invest 1998;101:847–
854.
Jacobsen W, Kirchner G, Hallensleben K, Mancinelli L, Deters M, Hackbarth I, Baner
K, Benet LZ, Sewing KF, Christians U. Small intestinal metabolism of the 3-
hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor lovastatin and compar-
ison with pravastatin. J Pharmacol Exp Ther 1999;291:131–139.
Jurima-Romet M, Crawford K, Cyr T, Inaba T. Terfenadine metabolism in human
liver.In vitroinhibition by macrolide antibiotics and azole antifungals. Drug Metab
Dispos 1994;22:849–857.
Kim RB. Transporters and drug discovery: why, when, and how. Mol Pharm 2006;3:26–32.
Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug
Discov 2004;3:711–715.
Li XQ, Andersson TB, Ahlstrom M, Weidolf L. Comparison of inhibitory effects of the
proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantopra-
zole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos
2004;32:821–827.
Marathe PH, Shyu WC, Humphreys WG. The use of radiolabeled compounds for
ADME studies in discovery and exploratory development. Curr Pharm Des
2004;10:2991–3008.
Niemi M, Backman JT, Granfors M, Laitila J, Neuvonen M, Neuvonen PJ. Gemfibrozil
considerably increases the plasma concentrations of rosiglitazone. Diabetologia
2003a;46:1319–1323.
Niemi M, Backman JT, Neuvonen M, Neuvonen PJ. Effects of gemfibrozil,
itraconazole, and their combination on the pharmacokinetics and pharmaco-
234 REGULATORY CONSIDERATIONS OF DRUG METABOLISM AND DRUG